Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.52 |
| ▸ | RPA1 | P27694 | 3/20 | 0.52 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | BCL2 | P10415 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915848 | 0.93 | CA9 (0.63) | CA9CHRNA7RPA1FAAHBCL2 | |
| SCHEMBL14504894 | 0.92 | CA9 (0.51) | CA9CHRNA7RPA1FAAHBCL2 | |
| SCHEMBL2917961 | 0.92 | CA9 (0.54) | CA9CHRNA7RPA1FAAHBCL2 | |
| SCHEMBL14504359 | 0.92 | CA9 (0.54) | CA9CHRNA7RPA1FAAHBCL2 | |
| SCHEMBL14504887 | 0.91 | MDM2 (0.53) | CA9CHRNA7RPA1FAAHBCL2 | |
| SCHEMBL2916480 | 0.91 | CHRNA7 (0.64) | CA9CHRNA7RPA1FAAHMALT1 | |
| SCHEMBL2913443 | 0.91 | CHRNA7 (0.64) | CA9CHRNA7FAAHBCL2MDM2 | |
| SCHEMBL2918939 | 0.91 | CA9 (0.63) | CA9CHRNA7RPA1FAAHBCL2 | |
| SCHEMBL9054421 | 0.89 | CA9 (0.65) | CA9CHRNA7RPA1FAAHBCL2 | |
| SCHEMBL2918178 | 0.89 | FAAH (0.58) | CA9CHRNA7RPA1FAAHPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | CA9 2908/4885CHRNA7 4696/4885RPA1 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.